This episode is Part 2 of our two-part conversation about the use of two drugs in a person's cancer journey which may be considered alternative to many people, cannabis and psilocybin. In this second episode we focus on psilocybin by talking to Mark Geyer, PhD, Distinguished Professor of Psychiatry and Neurosciences Emeritus at the University of California San Diego (UCSD), who directs the Neuropsychopharmacology Unit of the VISN 22 Veterans Administration Mental Illness Research, Clinical, and Education Center.
For four decades, his group has had continuous funding from the National Institute on Drug Abuse to study the behavioral effects of psychedelics and entactogens. At UCSD, he is a founding member of the Consortium for Translational Research in Neuropsychopharmacology (CTRIN) and Translational Research in Psychophysiology, Exploration, and Cognition (TRIPEC) groups.
As Dr. Geyer makes clear during our interview, the decision to use psilocybin should only be made with the professional guidance of medical experts; this is not a DIY treatment method.
About Clearity
Cancer Connections is produced by Clearity, which provides free support and services to people impacted by ovarian cancer. You can learn more about Clearity and the topics we've discussed today by visiting clearity.org. Or, feel free to email us your questions or comments at podcast@clearity.org. Thanks!